Menu Search
Equities

Innoviva Inc

INVA:NSQ

Innoviva Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)19.10
  • Today's Change0.04 / 0.21%
  • Shares traded127.47k
  • 1 Year change+40.75%
  • Beta0.5413
Data delayed at least 15 minutes, as of Nov 22 2024 16:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Innoviva Inc's revenues fell -6.30% from 331.34m to 310.46m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 213.92m to 179.72m, a -15.99% decrease.
Gross margin87.93%
Net profit margin18.31%
Operating margin45.71%
Return on assets5.34%
Return on equity9.97%
Return on investment5.98%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Innoviva Inc fell by 97.54m. However, the company earned 141.06m from its operations for a Cash Flow Margin of 45.44%. In addition the company used 66.76m on investing activities and also paid 171.84m in financing cash flows.
Cash flow per share1.42
Price/Cash flow per share11.42
Book value per share10.68
Tangible book value per share5.85
More ▼

Balance sheet in USDView more

Innoviva Inc has a Debt to Total Capital ratio of 40.11%, a lower figure than the previous year's 71.03%.
Current ratio1.79
Quick ratio1.64
Total debt/total equity0.6698
Total debt/total capital0.4011
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -3.06%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-8.76
EPS (TTM) vs
TTM 1 year ago		27.88
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.